X0609 4 2026-09-16 0 0001280776 IMMUNIC, INC. IMUX 0001055947 BVF PARTNERS L P/IL false 44 MONTGOMERY STREET 40TH FLOOR SAN FRANCISCO CA 94104 1 0 0 1 See Explanation of Responses 0000918923 BIOTECHNOLOGY VALUE FUND L P false 44 MONTGOMERY STREET 40TH FLOOR SAN FRANCISCO CA 94104 1 0 0 1 See Explanation of Responses 0001803805 BVF I GP LLC false 44 MONTGOMERY STREET 40TH FLOOR SAN FRANCISCO CA 94104 1 0 0 1 See Explanation of Responses 0001102444 BIOTECHNOLOGY VALUE FUND II LP false 44 MONTGOMERY STREET 40TH FLOOR SAN FRANCISCO CA 94104 1 0 0 1 See Explanation of Responses 0001803806 BVF II GP LLC false 44 MONTGOMERY STREET 40TH FLOOR SAN FRANCISCO CA 94104 1 0 0 1 See Explanation of Responses 0001660683 Biotechnology Value Trading Fund OS LP true P.O. BOX 309 UGLAND HOUSE GRAND CAYMAN E9 KY1-1104 CAYMAN ISLANDS 1 0 0 1 See Explanation of Responses 0001660684 BVF Partners OS Ltd. true P.O. BOX 309 UGLAND HOUSE GRAND CAYMAN E9 KY1-1104 CAYMAN ISLANDS 1 0 0 1 See Explanation of Responses 0001803809 BVF GP HOLDINGS LLC false 44 MONTGOMERY STREET 40TH FLOOR SAN FRANCISCO CA 94104 1 0 0 1 See Explanation of Responses 0001056807 BVF INC/IL false 44 MONTGOMERY STREET 40TH FLOOR SAN FRANCISCO CA 94104 1 0 0 1 See Explanation of Responses 0001233840 LAMPERT MARK N false 44 MONTGOMERY STREET 40TH FLOOR SAN FRANCISCO CA 94104 1 0 0 1 See Explanation of Responses 0 Common Stock, $0.0001 par value 413595 D Common Stock, $0.0001 par value 302710 D Common Stock, $0.0001 par value 42762 D Stock Option 10.12 2026-09-16 4 A 0 25370 0.00 A 2036-09-16 Common Stock, $0.0001 par value 25370 25370 I See footnote This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. Reflects a one-for-ten reverse stock split of the Issuer's issued and outstanding Common Stock, effective as of April 27, 2026 (the "Stock Split"). Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF. Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS. The option vests in monthly increments over a period of one year from the grant date. Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and R. Thorvald Nagel, who serves on the Issuer's board of directors and as a Principal of Partners, pursuant to which Mr. Nagel is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Nagel disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of the Reporting Persons may be deemed to be a director by deputization of the Issuer due to a Principal of Partners, R. Thorvald Nagel, serving on the Board of Directors of the Issuer, and his agreement to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President 2026-09-18 Biotechnology Value Fund, L.P., By: BVF I GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer 2026-09-18 BVF I GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer 2026-09-18 Biotechnology Value Fund II, L.P., By: BVF II GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer 2026-09-18 BVF II GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer 2026-09-18 BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President 2026-09-18 Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment manager, BVF Inc., its general partner, By: /s/ Mark N. Lampert, President 2026-09-18 BVF GP Holdings LLC, By: /s/ Mark N. Lampert, Chief Executive Officer 2026-09-18 BVF Inc., By: /s/ Mark N. Lampert, President 2026-09-18 /s/ Mark N. Lampert 2026-09-18